Detailed Information

Cited 16 time in webofscience Cited 12 time in scopus
Metadata Downloads

Natural history of metastatic biliary tract cancer (BTC) patients with good performance status (PS) who were treated with only best supportive care (BSC)

Authors
Ji, JH[Ji, Jun Ho]Song, HN[Song, Haa-Na]Kim, RB[Kim, Rock Bum]Oh, SY[Oh, Sung Yong]Lim, HY[Lim, Ho Yeong]Park, JO[Park, Joon Oh]Park, SH[Park, Se Hoon]Kim, MJ[Kim, Moon Jin]Lee, SI[Lee, Soon Il]Ryou, SH[Ryou, Sung Hyeok]Hwang, IG[Hwang, In Gyu]Jang, JS[Jang, Joung-Soon]Kim, HJ[Kim, Hong Jun]Choi, JY[Choi, Jun Young]Kang, JH[Kang, Jung-Hun]
Issue Date
Mar-2015
Publisher
OXFORD UNIV PRESS
Keywords
natural history; biliary tract cancer; best supportive care
Citation
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, v.45, no.3, pp.256 - 260
Indexed
SCIE
SCOPUS
Journal Title
JAPANESE JOURNAL OF CLINICAL ONCOLOGY
Volume
45
Number
3
Start Page
256
End Page
260
URI
https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/44433
DOI
10.1093/jjco/hyu210
ISSN
0368-2811
Abstract
Background: Although chemotherapy is widely recommended for patients with metastatic biliary tract cancer, the natural course of these patients, especially those with good performance status who are indicated for chemotherapy, is not known. Methods: We retrospectively reviewed patients with metastatic or locally advanced biliary cancer who were diagnosed at six cancer centers. Patients were eligible if they had good performance (ECOG 0-2) and no history of any treatment for cancer. The primary objective was to evaluate the survival time of patients with advanced biliary cancer with good performance who were untreated. Results: Of the 1677 patients, 204 met the inclusion criteria. The median age and overall survival were 72.0 years and 7.1 months. Overall survival (months) by location was 4.7 for intrahepatic, 9.7 for extrahepatic, 4.4 for gallbladder and 11.2 for ampulla of vater cancer. In subgroup analysis, overall survival of locally advanced biliary cancer was 13.8 months and that of patients with normal carcinoembryonic antigen/carbohydrate antigen 19-9 was 10.6 months. In multivariate analysis, variables that were associated with poor prognosis were metastatic biliary cancer [hazard ratio 2.19 (P = 0.001)], high baseline carcinoembryonic antigen level (defined as > 4.0 ng/ml) [hazard ratio 1.51 (P = 0.024)] and high baseline carbohydrate antigen 19-9 level (defined as > 100 U/ml) [hazard ratio 1.93 (P = 0.001)]. Conclusions: Advanced biliary tract cancer with good performance status showed modest survival without any treatment. Furthermore, subgroup analysis showed that patients with normal carbohydrate antigen 19-9 or carcinoembryonic antigen level or locally advanced status had favorable survival. Further studies comparing the outcome of chemotherapy with that of best supportive care in patients with unresectable biliary tract cancer are warranted.
Files in This Item
There are no files associated with this item.
Appears in
Collections
Medicine > Department of Medicine > 1. Journal Articles

qrcode

Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.

Related Researcher

Researcher LIM, HO YEONG photo

LIM, HO YEONG
Medicine (Medicine)
Read more

Altmetrics

Total Views & Downloads

BROWSE